Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 94

1.

Interleukin-32 Contributes to Human Nonalcoholic Fatty Liver Disease and Insulin Resistance.

Dali-Youcef N, Vix M, Costantino F, El-Saghire H, Lhermitte B, Callari C, D'Agostino J, Perretta S, Paveliu S, Gualtierotti M, Dumeny E, Oudot MA, Jaulin A, Dembélé D, Zeisel MB, Tomasetto C, Baumert TF, Doffoël M.

Hepatol Commun. 2019 Jul 19;3(9):1205-1220. doi: 10.1002/hep4.1396. eCollection 2019 Sep.

2.

Functional microRNA screen uncovers O-linked N-acetylglucosamine transferase as a host factor modulating hepatitis C virus morphogenesis and infectivity.

Herzog K, Bandiera S, Pernot S, Fauvelle C, Jühling F, Weiss A, Bull A, Durand SC, Chane-Woon-Ming B, Pfeffer S, Mercey M, Lerat H, Meunier JC, Raffelsberger W, Brino L, Baumert TF, Zeisel MB.

Gut. 2019 May 10. pii: gutjnl-2018-317423. doi: 10.1136/gutjnl-2018-317423. [Epub ahead of print]

PMID:
31076402
3.

Interferon-Induced Transmembrane Proteins Mediate Viral Evasion in Acute and Chronic Hepatitis C Virus Infection.

Wrensch F, Ligat G, Heydmann L, Schuster C, Zeisel MB, Pessaux P, Habersetzer F, King BJ, Tarr AW, Ball JK, Winkler M, Pöhlmann S, Keck ZY, Foung SKH, Baumert TF.

Hepatology. 2019 Nov;70(5):1506-1520. doi: 10.1002/hep.30699. Epub 2019 Jun 21.

PMID:
31062385
4.

Combined Analysis of Metabolomes, Proteomes, and Transcriptomes of Hepatitis C Virus-Infected Cells and Liver to Identify Pathways Associated With Disease Development.

Lupberger J, Croonenborghs T, Roca Suarez AA, Van Renne N, Jühling F, Oudot MA, Virzì A, Bandiera S, Jamey C, Meszaros G, Brumaru D, Mukherji A, Durand SC, Heydmann L, Verrier ER, El Saghire H, Hamdane N, Bartenschlager R, Fereshetian S, Ramberger E, Sinha R, Nabian M, Everaert C, Jovanovic M, Mertins P, Carr SA, Chayama K, Dali-Youcef N, Ricci R, Bardeesy NM, Fujiwara N, Gevaert O, Zeisel MB, Hoshida Y, Pochet N, Baumert TF.

Gastroenterology. 2019 Aug;157(2):537-551.e9. doi: 10.1053/j.gastro.2019.04.003. Epub 2019 Apr 9.

PMID:
30978357
5.

HCV-Induced Epigenetic Changes Associated With Liver Cancer Risk Persist After Sustained Virologic Response.

Hamdane N, Jühling F, Crouchet E, El Saghire H, Thumann C, Oudot MA, Bandiera S, Saviano A, Ponsolles C, Roca Suarez AA, Li S, Fujiwara N, Ono A, Davidson I, Bardeesy N, Schmidl C, Bock C, Schuster C, Lupberger J, Habersetzer F, Doffoël M, Piardi T, Sommacale D, Imamura M, Uchida T, Ohdan H, Aikata H, Chayama K, Boldanova T, Pessaux P, Fuchs BC, Hoshida Y, Zeisel MB, Duong FHT, Baumert TF.

Gastroenterology. 2019 Jun;156(8):2313-2329.e7. doi: 10.1053/j.gastro.2019.02.038. Epub 2019 Mar 2.

6.

Combined small molecule and loss-of-function screen uncovers estrogen receptor alpha and CAD as host factors for HDV infection and antiviral targets.

Verrier ER, Weiss A, Bach C, Heydmann L, Turon-Lagot V, Kopp A, El Saghire H, Crouchet E, Pessaux P, Garcia T, Pale P, Zeisel MB, Sureau C, Schuster C, Brino L, Baumert TF.

Gut. 2020 Jan;69(1):158-167. doi: 10.1136/gutjnl-2018-317065. Epub 2019 Mar 4.

7.

In vivo combination of human anti-envelope glycoprotein E2 and -Claudin-1 monoclonal antibodies for prevention of hepatitis C virus infection.

Mailly L, Wrensch F, Heydmann L, Fauvelle C, Brignon N, Zeisel MB, Pessaux P, Keck ZY, Schuster C, Fuerst TR, Foung SKH, Baumert TF.

Antiviral Res. 2019 Feb;162:136-141. doi: 10.1016/j.antiviral.2018.12.018. Epub 2018 Dec 30.

PMID:
30599173
8.

Non-Coding RNAs and Hepatitis C Virus-Induced Hepatocellular Carcinoma.

Plissonnier ML, Herzog K, Levrero M, Zeisel MB.

Viruses. 2018 Oct 30;10(11). pii: E591. doi: 10.3390/v10110591. Review.

9.

Tight junction proteins in gastrointestinal and liver disease.

Zeisel MB, Dhawan P, Baumert TF.

Gut. 2018 Oct 8. pii: gutjnl-2018-316906. doi: 10.1136/gutjnl-2018-316906. [Epub ahead of print] Review.

10.

Hepatitis C Virus (HCV)-Apolipoprotein Interactions and Immune Evasion and Their Impact on HCV Vaccine Design.

Wrensch F, Crouchet E, Ligat G, Zeisel MB, Keck ZY, Foung SKH, Schuster C, Baumert TF.

Front Immunol. 2018 Jun 21;9:1436. doi: 10.3389/fimmu.2018.01436. eCollection 2018. Review.

11.

[Risk of hepatocellular carcinoma after hepatitis C virus cure with direct-acting antivirals: the next challenges].

Hamdane N, Baumert TF, Zeisel MB.

Med Sci (Paris). 2018 May;34(5):391-394. doi: 10.1051/medsci/20183405007. Epub 2018 Jun 13. French. No abstract available.

12.

Hepatitis B Virus Evasion From Cyclic Guanosine Monophosphate-Adenosine Monophosphate Synthase Sensing in Human Hepatocytes.

Verrier ER, Yim SA, Heydmann L, El Saghire H, Bach C, Turon-Lagot V, Mailly L, Durand SC, Lucifora J, Durantel D, Pessaux P, Manel N, Hirsch I, Zeisel MB, Pochet N, Schuster C, Baumert TF.

Hepatology. 2018 Nov;68(5):1695-1709. doi: 10.1002/hep.30054. Epub 2018 Jul 10.

13.

Host-targeting therapies for hepatitis C virus infection: current developments and future applications.

Crouchet E, Wrensch F, Schuster C, Zeisel MB, Baumert TF.

Therap Adv Gastroenterol. 2018 Mar 21;11:1756284818759483. doi: 10.1177/1756284818759483. eCollection 2018. Review.

14.

Plasmodium P36 determines host cell receptor usage during sporozoite invasion.

Manzoni G, Marinach C, Topçu S, Briquet S, Grand M, Tolle M, Gransagne M, Lescar J, Andolina C, Franetich JF, Zeisel MB, Huby T, Rubinstein E, Snounou G, Mazier D, Nosten F, Baumert TF, Silvie O.

Elife. 2017 May 16;6. pii: e25903. doi: 10.7554/eLife.25903.

15.

Toward novel immunocompetent animal models for hepatitis B virus infection.

Mailly L, Zeisel MB, Baumert TF.

Hepatology. 2017 Sep;66(3):691-693. doi: 10.1002/hep.29249. Epub 2017 Jul 20. No abstract available.

PMID:
28470681
16.

Humanisation of a claudin-1-specific monoclonal antibody for clinical prevention and cure of HCV infection without escape.

Colpitts CC, Tawar RG, Mailly L, Thumann C, Heydmann L, Durand SC, Xiao F, Robinet E, Pessaux P, Zeisel MB, Baumert TF.

Gut. 2018 Apr;67(4):736-745. doi: 10.1136/gutjnl-2016-312577. Epub 2017 Mar 30.

17.

miR-135a-5p-mediated downregulation of protein tyrosine phosphatase receptor delta is a candidate driver of HCV-associated hepatocarcinogenesis.

Van Renne N, Roca Suarez AA, Duong FHT, Gondeau C, Calabrese D, Fontaine N, Ababsa A, Bandiera S, Croonenborghs T, Pochet N, De Blasi V, Pessaux P, Piardi T, Sommacale D, Ono A, Chayama K, Fujita M, Nakagawa H, Hoshida Y, Zeisel MB, Heim MH, Baumert TF, Lupberger J.

Gut. 2018 May;67(5):953-962. doi: 10.1136/gutjnl-2016-312270. Epub 2017 Feb 3.

18.

Clinical development of hepatitis C virus host-targeting agents.

Zeisel MB, Baumert TF.

Lancet. 2017 Feb 18;389(10070):674-675. doi: 10.1016/S0140-6736(17)30043-0. Epub 2017 Jan 11. No abstract available.

19.

Solute Carrier NTCP Regulates Innate Antiviral Immune Responses Targeting Hepatitis C Virus Infection of Hepatocytes.

Verrier ER, Colpitts CC, Bach C, Heydmann L, Zona L, Xiao F, Thumann C, Crouchet E, Gaudin R, Sureau C, Cosset FL, McKeating JA, Pessaux P, Hoshida Y, Schuster C, Zeisel MB, Baumert TF.

Cell Rep. 2016 Oct 25;17(5):1357-1368. doi: 10.1016/j.celrep.2016.09.084.

20.

Broad neutralization of hepatitis C virus-resistant variants by Civacir hepatitis C immunoglobulin.

Tawar RG, Heydmann L, Bach C, Schüttrumpf J, Chavan S, King BJ, McClure CP, Ball JK, Pessaux P, Habersetzer F, Bartenschlager R, Zeisel MB, Baumert TF.

Hepatology. 2016 Nov;64(5):1495-1506. doi: 10.1002/hep.28767. Epub 2016 Sep 30.

PMID:
27531416
21.

Chronic hepatitis C virus infection and pathogenesis of hepatocellular carcinoma.

Bandiera S, Billie Bian C, Hoshida Y, Baumert TF, Zeisel MB.

Curr Opin Virol. 2016 Oct;20:99-105. doi: 10.1016/j.coviro.2016.09.010. Epub 2016 Oct 11. Review.

22.

Cell Culture Models for the Investigation of Hepatitis B and D Virus Infection.

Verrier ER, Colpitts CC, Schuster C, Zeisel MB, Baumert TF.

Viruses. 2016 Sep 20;8(9). pii: E261. Review.

23.

Hepatitis B virus: is a cure possible?

Zeisel MB, Baumert TF.

Expert Rev Clin Pharmacol. 2016 Sep;9(9):1129-30. doi: 10.1080/17512433.2016.1206466. Epub 2016 Jul 13. No abstract available.

PMID:
27347775
24.

Circulating microRNAs for early detection of hepatitis B-related hepatocellular carcinoma.

Bandiera S, Baumert TF, Zeisel MB.

Hepatobiliary Surg Nutr. 2016 Jun;5(3):198-200. doi: 10.21037/hbsn.2016.03.08. No abstract available.

25.

Translation and protein expression of lncRNAs: Impact for liver disease and hepatocellular carcinoma.

Zeisel MB, Baumert TF.

Hepatology. 2016 Aug;64(2):671-4. doi: 10.1002/hep.28653. Epub 2016 Jun 24. No abstract available.

PMID:
27228461
26.

Hepatitis C Virus-Induced Upregulation of MicroRNA miR-146a-5p in Hepatocytes Promotes Viral Infection and Deregulates Metabolic Pathways Associated with Liver Disease Pathogenesis.

Bandiera S, Pernot S, El Saghire H, Durand SC, Thumann C, Crouchet E, Ye T, Fofana I, Oudot MA, Barths J, Schuster C, Pessaux P, Heim MH, Baumert TF, Zeisel MB.

J Virol. 2016 Jun 24;90(14):6387-6400. doi: 10.1128/JVI.00619-16. Print 2016 Jul 15.

27.

Addressing the next challenges: A summary of the 22nd international symposium on hepatitis C virus and related viruses.

Baumert TF, Schuster C, Cosset FL, Dubuisson J, Hofmann M, Tautz N, Zeisel MB, Thimme R.

J Hepatol. 2016 Apr;64(4):968-73. doi: 10.1016/j.jhep.2015.12.021. Epub 2016 Jan 11. Review.

PMID:
26780288
28.

[Locked outside: cure of chronic hepatitis C using an entry inhibitor].

Mailly L, Zeisel MB, Baumert TF.

Med Sci (Paris). 2015 Dec;31(12):1075-7. doi: 10.1051/medsci/20153112009. Epub 2015 Dec 16. French. No abstract available.

29.

Host-Targeting Agents to Prevent and Cure Hepatitis C Virus Infection.

Zeisel MB, Crouchet E, Baumert TF, Schuster C.

Viruses. 2015 Nov 2;7(11):5659-85. doi: 10.3390/v7112898. Review.

30.

Apolipoprotein E Mediates Evasion From Hepatitis C Virus Neutralizing Antibodies.

Fauvelle C, Felmlee DJ, Crouchet E, Lee J, Heydmann L, Lefèvre M, Magri A, Hiet MS, Fofana I, Habersetzer F, Foung SK, Milne R, Patel AH, Vercauteren K, Meuleman P, Zeisel MB, Bartenschlager R, Schuster C, Baumert TF.

Gastroenterology. 2016 Jan;150(1):206-217.e4. doi: 10.1053/j.gastro.2015.09.014. Epub 2015 Sep 25.

PMID:
26404951
31.

Host-targeting agents for treatment of hepatitis B virus infection.

Baumert TF, Verrier ER, Nassal M, Chung RT, Zeisel MB.

Curr Opin Virol. 2015 Oct;14:41-6. doi: 10.1016/j.coviro.2015.07.009. Epub 2015 Aug 8. Review.

PMID:
26262886
32.

A targeted functional RNA interference screen uncovers glypican 5 as an entry factor for hepatitis B and D viruses.

Verrier ER, Colpitts CC, Bach C, Heydmann L, Weiss A, Renaud M, Durand SC, Habersetzer F, Durantel D, Abou-Jaoudé G, López Ledesma MM, Felmlee DJ, Soumillon M, Croonenborghs T, Pochet N, Nassal M, Schuster C, Brino L, Sureau C, Zeisel MB, Baumert TF.

Hepatology. 2016 Jan;63(1):35-48. doi: 10.1002/hep.28013. Epub 2015 Oct 6.

PMID:
26224662
33.

Functional and Biochemical Characterization of Hepatitis C Virus (HCV) Particles Produced in a Humanized Liver Mouse Model.

Calattini S, Fusil F, Mancip J, Dao Thi VL, Granier C, Gadot N, Scoazec JY, Zeisel MB, Baumert TF, Lavillette D, Dreux M, Cosset FL.

J Biol Chem. 2015 Sep 18;290(38):23173-87. doi: 10.1074/jbc.M115.662999. Epub 2015 Jul 29.

34.

Acute hepatitis C virus infection induces anti-host cell receptor antibodies with virus-neutralizing properties.

Tawar RG, Colpitts CC, Timm J, Fehm T, Roggendorf M, Meisel H, Meyer N, Habersetzer F, Cosset FL, Berg T, Zeisel MB, Baumert TF.

Hepatology. 2015 Sep;62(3):726-36. doi: 10.1002/hep.27906. Epub 2015 Jul 28.

PMID:
26010076
35.

Claudins and pathogenesis of viral infection.

Tawar RG, Colpitts CC, Lupberger J, El-Saghire H, Zeisel MB, Baumert TF.

Semin Cell Dev Biol. 2015 Jun;42:39-46. doi: 10.1016/j.semcdb.2015.04.011. Epub 2015 May 7. Review.

PMID:
25960372
36.

When one receptor closes, another opens: claudins and the hepatitis C virus E1 glycoprotein.

Colpitts CC, Zeisel MB, Baumert TF.

Hepatology. 2015 Oct;62(4):991-3. doi: 10.1002/hep.27876. Epub 2015 Jun 17. No abstract available.

PMID:
25930717
37.

Clearance of persistent hepatitis C virus infection in humanized mice using a claudin-1-targeting monoclonal antibody.

Mailly L, Xiao F, Lupberger J, Wilson GK, Aubert P, Duong FHT, Calabrese D, Leboeuf C, Fofana I, Thumann C, Bandiera S, Lütgehetmann M, Volz T, Davis C, Harris HJ, Mee CJ, Girardi E, Chane-Woon-Ming B, Ericsson M, Fletcher N, Bartenschlager R, Pessaux P, Vercauteren K, Meuleman P, Villa P, Kaderali L, Pfeffer S, Heim MH, Neunlist M, Zeisel MB, Dandri M, McKeating JA, Robinet E, Baumert TF.

Nat Biotechnol. 2015 May;33(5):549-554. doi: 10.1038/nbt.3179. Epub 2015 Mar 23.

38.

Towards an HBV cure: state-of-the-art and unresolved questions--report of the ANRS workshop on HBV cure.

Zeisel MB, Lucifora J, Mason WS, Sureau C, Beck J, Levrero M, Kann M, Knolle PA, Benkirane M, Durantel D, Michel ML, Autran B, Cosset FL, Strick-Marchand H, Trépo C, Kao JH, Carrat F, Lacombe K, Schinazi RF, Barré-Sinoussi F, Delfraissy JF, Zoulim F.

Gut. 2015 Aug;64(8):1314-26. doi: 10.1136/gutjnl-2014-308943. Epub 2015 Feb 10. Review.

PMID:
25670809
39.

miR-122--a key factor and therapeutic target in liver disease.

Bandiera S, Pfeffer S, Baumert TF, Zeisel MB.

J Hepatol. 2015 Feb;62(2):448-57. doi: 10.1016/j.jhep.2014.10.004. Epub 2014 Oct 13. Review.

40.

Role of hypervariable region 1 for the interplay of hepatitis C virus with entry factors and lipoproteins.

Bankwitz D, Vieyres G, Hueging K, Bitzegeio J, Doepke M, Chhatwal P, Haid S, Catanese MT, Zeisel MB, Nicosia A, Baumert TF, Kaderali L, Pietschmann T.

J Virol. 2014 Nov;88(21):12644-55. doi: 10.1128/JVI.01145-14. Epub 2014 Aug 20.

41.

Synergy of entry inhibitors with direct-acting antivirals uncovers novel combinations for prevention and treatment of hepatitis C.

Xiao F, Fofana I, Thumann C, Mailly L, Alles R, Robinet E, Meyer N, Schaeffer M, Habersetzer F, Doffoël M, Leyssen P, Neyts J, Zeisel MB, Baumert TF.

Gut. 2015 Mar;64(3):483-94. doi: 10.1136/gutjnl-2013-306155. Epub 2014 May 21.

42.

Hepatitis C virus cell-cell transmission and resistance to direct-acting antiviral agents.

Xiao F, Fofana I, Heydmann L, Barth H, Soulier E, Habersetzer F, Doffoël M, Bukh J, Patel AH, Zeisel MB, Baumert TF.

PLoS Pathog. 2014 May 15;10(5):e1004128. doi: 10.1371/journal.ppat.1004128. eCollection 2014 May.

43.

IFN-λ receptor 1 expression is induced in chronic hepatitis C and correlates with the IFN-λ3 genotype and with nonresponsiveness to IFN-α therapies.

Duong FH, Trincucci G, Boldanova T, Calabrese D, Campana B, Krol I, Durand SC, Heydmann L, Zeisel MB, Baumert TF, Heim MH.

J Exp Med. 2014 May 5;211(5):857-68. doi: 10.1084/jem.20131557. Epub 2014 Apr 21.

44.

CD81-receptor associations--impact for hepatitis C virus entry and antiviral therapies.

Zona L, Tawar RG, Zeisel MB, Xiao F, Schuster C, Lupberger J, Baumert TF.

Viruses. 2014 Feb 18;6(2):875-92. doi: 10.3390/v6020875. Review.

45.

[Research on hepatitis c and therapeutic options].

Zeisel MB, Baumert TF.

Soins. 2013 Nov;(780):53. French. No abstract available.

PMID:
24409623
46.

Genetically humanized mice recapitulate the entire hepatitis C virus life cycle.

Mailly L, Zeisel MB, Baumert TF.

J Hepatol. 2014 Mar;60(3):671-3. doi: 10.1016/j.jhep.2013.10.005. Epub 2013 Oct 12. No abstract available.

47.

Critical interaction between E1 and E2 glycoproteins determines binding and fusion properties of hepatitis C virus during cell entry.

Douam F, Dao Thi VL, Maurin G, Fresquet J, Mompelat D, Zeisel MB, Baumert TF, Cosset FL, Lavillette D.

Hepatology. 2014 Mar;59(3):776-88. doi: 10.1002/hep.26733. Epub 2014 Jan 28.

PMID:
24038151
48.

Hepatitis C virus infection and related liver disease: the quest for the best animal model.

Mailly L, Robinet E, Meuleman P, Baumert TF, Zeisel MB.

Front Microbiol. 2013 Jul 26;4:213. doi: 10.3389/fmicb.2013.00212. eCollection 2013.

49.

Functional analysis of claudin-6 and claudin-9 as entry factors for hepatitis C virus infection of human hepatocytes by using monoclonal antibodies.

Fofana I, Zona L, Thumann C, Heydmann L, Durand SC, Lupberger J, Blum HE, Pessaux P, Gondeau C, Reynolds GM, McKeating JA, Grunert F, Thompson J, Zeisel MB, Baumert TF.

J Virol. 2013 Sep;87(18):10405-10. doi: 10.1128/JVI.01691-13. Epub 2013 Jul 17.

50.

Genotype 1 hepatitis C virus envelope features that determine antiviral response assessed through optimal covariance networks.

Murray JM, Moenne-Loccoz R, Velay A, Habersetzer F, Doffoël M, Gut JP, Fofana I, Zeisel MB, Stoll-Keller F, Baumert TF, Schvoerer E.

PLoS One. 2013 Jun 20;8(6):e67254. doi: 10.1371/journal.pone.0067254. Print 2013.

Supplemental Content

Loading ...
Support Center